ERC Advanced Grant · 2023
Harnessing RARA signalling for curative AML therapies
In acute promyelocytic leukaemia (APL), retinoic acid (RA) and arsenic trioxide (ATO) bind the PML/RARA fusion to promote its degradation, derepressing unknown master regulatory genes and activating a PML/P53 checkpoint which is required for APL cure. APL initiation deregulates Retinoic Acid Receptor a (RARA) signalling. These deregulations are likely shared with a sizable subset of non-APL acute myeloid leukaemia (AML): the 30% that overexpress normal RARA and exhibit some RA-sensitivity ex vivo. Clinical trials have demonstrated some benefit of RA addition to conventional therapies in non-APL AML patients, but have not resulted in the incorporation of RA into standard therapies. Thus,…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at National Institute of Health and Medical Research (INSERM)